109 related articles for article (PubMed ID: 38277917)
1. Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability.
Xu J; Zhao A; Chen D; Wang J; Ma J; Qing L; Li Y; Fang H; He H; Pan W; Zhang S
Eur J Med Chem; 2024 Feb; 266():116160. PubMed ID: 38277917
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors.
Gu H; Yan W; Wang Y; Xu W; Huang L; Yang J; Zhai B; Wang H; Su Y; Zhu Q; Liu B; Hao H; Zou Y; Xu Y
J Med Chem; 2023 Jan; 66(1):473-490. PubMed ID: 36576395
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy.
Gu H; Yan W; Yang J; Liu B; Zhao X; Wang H; Xu W; Wang C; Chen Y; Dong Q; Zhu Q; Xu Y; Zou Y
J Med Chem; 2024 Feb; 67(3):1932-1948. PubMed ID: 38059836
[TBL] [Abstract][Full Text] [Related]
4. Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors.
Zhang S; Zhang Y; Wang Z; Qing L; Fu S; Xu J; Li Y; Fang H; He H
Eur J Med Chem; 2023 Dec; 261():115836. PubMed ID: 37826932
[TBL] [Abstract][Full Text] [Related]
5. Discovery of highly potent PARP7 inhibitors for cancer immunotherapy.
Yang J; Liu B; Yan W; Zhao X; Wang C; Zhu Q; Zou Y; Xu Y; Gu H
Bioorg Chem; 2024 Jul; 148():107469. PubMed ID: 38781669
[TBL] [Abstract][Full Text] [Related]
6. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.
Gozgit JM; Vasbinder MM; Abo RP; Kunii K; Kuplast-Barr KG; Gui B; Lu AZ; Molina JR; Minissale E; Swinger KK; Wigle TJ; Blackwell DJ; Majer CR; Ren Y; Niepel M; Varsamis ZA; Nayak SP; Bamberg E; Mo JR; Church WD; Mady ASA; Song J; Utley L; Rao PE; Mitchison TJ; Kuntz KW; Richon VM; Keilhack H
Cancer Cell; 2021 Sep; 39(9):1214-1226.e10. PubMed ID: 34375612
[TBL] [Abstract][Full Text] [Related]
7. Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
Jain MR; Mohapatra J; Bandhyopadhyay D; Chatterjee A; Ghoshdastidar K; Patel D; Patel A; Bhayani H; Srivastava BK; Shedage SA; Kadam P; Sundar R; Patel H; Giri P; Patel P; Gupta L; Srinivas NR; Patel PR; Desai RC
Cancer Chemother Pharmacol; 2018 Oct; 82(4):635-647. PubMed ID: 30046848
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Quinazoline-2,4(1
Zhou J; Ji M; Wang X; Zhao H; Cao R; Jin J; Li Y; Chen X; Sheng L; Chen X; Xu B
J Med Chem; 2021 Nov; 64(22):16711-16730. PubMed ID: 34748333
[TBL] [Abstract][Full Text] [Related]
9. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel Bromophenol-Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer.
Guo C; Wang L; Li X; Wang S; Yu X; Xu K; Zhao Y; Luo J; Li X; Jiang B; Shi D
J Med Chem; 2019 Mar; 62(6):3051-3067. PubMed ID: 30844273
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
[TBL] [Abstract][Full Text] [Related]
13. PARP7 and Mono-ADP-Ribosylation Negatively Regulate Estrogen Receptor α Signaling in Human Breast Cancer Cells.
Rasmussen M; Tan S; Somisetty VS; Hutin D; Olafsen NE; Moen A; Anonsen JH; Grant DM; Matthews J
Cells; 2021 Mar; 10(3):. PubMed ID: 33799807
[TBL] [Abstract][Full Text] [Related]
14. Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-β signaling.
Sanderson DJ; Rodriguez KM; Bejan DS; Olafsen NE; Bohn ID; Kojic A; Sundalam S; Siordia IR; Duell AK; Deng N; Schultz C; Grant DM; Matthews J; Cohen MS
Cell Chem Biol; 2023 Jan; 30(1):43-54.e8. PubMed ID: 36529140
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.
Anumala UR; Waaler J; Nkizinkiko Y; Ignatev A; Lazarow K; Lindemann P; Olsen PA; Murthy S; Obaji E; Majouga AG; Leonov S; von Kries JP; Lehtiö L; Krauss S; Nazaré M
J Med Chem; 2017 Dec; 60(24):10013-10025. PubMed ID: 29155568
[TBL] [Abstract][Full Text] [Related]
16. Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
Karche NP; Bhonde M; Sinha N; Jana G; Kukreja G; Kurhade SP; Jagdale AR; Tilekar AR; Hajare AK; Jadhav GR; Gupta NR; Limaye R; Khedkar N; Thube BR; Shaikh JS; Rao Irlapati N; Phukan S; Gole G; Bommakanti A; Khanwalkar H; Pawar Y; Kale R; Kumar R; Gupta R; Praveen Kumar VR; Wahid S; Francis A; Bhat T; Kamble N; Patil V; Nigade PB; Modi D; Pawar S; Naidu S; Volam H; Pagdala V; Mallurwar S; Goyal H; Bora P; Ahirrao P; Singh M; Kamalakannan P; Naik KR; Kumar P; Powar RG; Shankar RB; Bernstein PR; Gundu J; Nemmani K; Narasimham L; George KS; Sharma S; Bakhle D; Kamboj RK; Palle VP
Bioorg Med Chem; 2020 Dec; 28(24):115819. PubMed ID: 33120078
[TBL] [Abstract][Full Text] [Related]
17. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
Wang LM; Wang P; Chen XM; Yang H; Song SS; Song Z; Jia L; Chen HD; Bao XB; Guo N; Huan XJ; Xi Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Chen Y; Ding J; Lang JY; Miao ZH; Zhang A; He JX
EMBO Mol Med; 2023 Mar; 15(3):e16235. PubMed ID: 36652375
[TBL] [Abstract][Full Text] [Related]
18. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
[TBL] [Abstract][Full Text] [Related]
19. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Donawho CK; Luo Y; Luo Y; Penning TD; Bauch JL; Bouska JJ; Bontcheva-Diaz VD; Cox BF; DeWeese TL; Dillehay LE; Ferguson DC; Ghoreishi-Haack NS; Grimm DR; Guan R; Han EK; Holley-Shanks RR; Hristov B; Idler KB; Jarvis K; Johnson EF; Kleinberg LR; Klinghofer V; Lasko LM; Liu X; Marsh KC; McGonigal TP; Meulbroek JA; Olson AM; Palma JP; Rodriguez LE; Shi Y; Stavropoulos JA; Tsurutani AC; Zhu GD; Rosenberg SH; Giranda VL; Frost DJ
Clin Cancer Res; 2007 May; 13(9):2728-37. PubMed ID: 17473206
[TBL] [Abstract][Full Text] [Related]
20. A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor.
Chen H; Diolaiti ME; O'Leary PC; Rojc A; Krogan NJ; Kim M; Ashworth A
Mol Cancer Ther; 2022 Jul; 21(7):1076-1089. PubMed ID: 35439318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
